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Abstract
·AIM: To compare the efficacy of single -session 360-
degree selective laser trabeculoplasty (SLT) for reduction
of intraocular pressure (IOP) in patients with
pseudoexfoliative glaucoma (PXFG) and primary open
angle glaucoma (POAG).
· METHODS: This is a single -center, prospective,
nonrandomized comparative study. Patients older than 18
years of age with uncontrolled PXFG or POAG eyes
requiring additional therapy while on maximally tolerated
IOP -lowering medications were included. The primary
outcome measure changed in IOP from baseline.
Success was defined as IOP reduction 逸20% from
baseline without any additional IOP-lowering medication.
All patients were examined at 1d, 1wk, 1, 3, 6, 9, 12mo
after SLT.
·RESULTS: Nineteen patients (20 eyes) with PXFG and
27 patients (28 eyes) with POAG were included in the
study. In the visual fields mean deviation was -2.88 (依1.67)
in the POAG and -3.1 (依1.69) in the PXFG groups ( =0.3).
The mean (依SD) IOP was 22.9 (依3.7) mm Hg in the POAG
group and 25.7 (依4.4) mm Hg in the PXFG group at
baseline and decreased to 18.4 (依3.2) and 18.0 (依3.9) mm Hg
in the POAG group ( <0.001 and =0.02), and to 17.9 (依
4.0) and 21.0 (依6.6) mm Hg in the PXFG group ( <0.001
and =0.47) at 6 and 12mo, respectively. The number of
medications was 2.6 (依0.8) in the POAG group and 2.5 (依
0.8) in the PXFG group at baseline, and did not change
at all follow-up visits in both groups ( =0.16 in POAG
and 0.57 in PXFG). Based on Kaplan -Meier survival
analysis, the success rate was 75% in the POAG group
compared to 94.1% in the PXFG group ( =0.08; Log-rank
test) at 6mo, and 29.1% and 25.0% at 12mo, respectively
( =0.9; Log-rank).
·CONCLUSION: The 360-degree SLT is an effective and
well-tolerated therapeutic modality in patients with POAG
and PXFG by reducing IOP without any change in
number of medications. The response was more
pronounced early in the postoperative period in patients
with PXFG whereas there was no statistically significant
difference at 12-month follow-up.
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INTRODUCTION
S elective laser trabeculoplasty (SLT) was introduced byLatina and Park in 1995 as an option for the treatment of
open angle glaucoma [1]. In this method, a Q-switched,
frequency doubled laser with a wavelength of 532 nm and
pulse duration of 3ns affects only the pigmented trabecular
meshwork cells while the non-pigmented meshwork cells
remain intact [2-3]. SLT has been widely adopted for treatment
of glaucoma and is used by some clinicians early in the
course of treatment of the disease [4-5]. Results of different
studies have shown that SLT reduces the intraocular pressure
(IOP) between 11% to 40% in various types of glaucoma in
short to intermediate-term period [6]. The exact mechanism
remains uncertain by which SLT reduces IOP but in
particular, cytokine secretion, matrix metalloproteinase
induction, increased cell division, repopulation of burn sites
and macrophage recruitment are responsible for IOP
reduction[7].
Although the efficacy of SLT in patients with primary open
angle glaucoma (POAG) has been well documented, there
are few studies that have investigated its efficacy in other
types of glaucoma including pigmentary and
pseudoexfoliative glaucoma (PXFG) [8-9]. In this prospective
study, we compared the efficacy of 360-degree SLT
treatment in patients with PXFG to those with POAG.
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SUBJECTS AND METHODS
Study Subjects This single-center, prospective,
nonrandomized comparative study was performed between
March 2010 and March 2013 at the Hazrat Rasoul Akram
Hospital, Tehran, Iran. The Ethics Committee at Iran
University of Medical Sciences, Tehran, Iran, approved the
study protocol. Written informed consents were obtained
from all patients and the study was carried out in accordance
with the principles of Declaration of Helsinki.
Patients aged 18 years or older with uncontrolled PXFG or
POAG requiring additional therapy while on maximally
tolerated IOP-lowering medications were enrolled. Exclusion
criteria were eyes with prior history of laser or incisional
surgery such as phacoemulsification, glaucoma procedures or
argon laser trabeculoplasty; ocular trauma or any other
preexisting corneal disease precluding the angle evaluation;
or if the trabecular meshwork could not be viewed for 360
degrees. Preoperative exams included slit-lamp
biomicroscopy, IOP measurement using Goldmann
applanation tonometry, gonioscopy, dilated fundoscopic
examination with a 90 D lens, and standard automated
perimetry with 24-2 Swedish interactive threshold Algorithm
(SITA; Carl Zeiss Meditec Inc. Dublin, CA, USA).
Outcome Measures The primary outcome measure was IOP
(mm Hg) before and after 360-degree SLT in both groups at
1d, 1wk and then every 3mo after surgery. All of IOP
measurements performed at morning in sitting position. Other
outcome measures included success rate, changes in the
number of IOP-lowering medications, and complications.
Success was defined as IOP reduction 逸20% from the
baseline without additional IOP-lowering medications. Failure
was defined as IOP reduction <20% from the baseline at two
consecutive visits and/or addition of IOP-lowering
medications.
Laser Procedure All the study eyes underwent 360-degree
SLT for the first time. All the procedures were performed by
two surgeons (Miraftabi A or Nilforushan N) with the same
protocol, which included -switched frequency-doubled
532 nm Nd:YAG laser (Ellex Tango SLT/Photodistruptor
Combination Laser, Ellex Medical Lasers Ltd., Adelaide,
Australia) with pulse duration of 3ns and a spot size of 400 滋m
for 360 degrees. No pretreatment with IOP-lowering
medications was used. After topical anesthesia with 0.5%
tetracaine hydrochloride, a laser goniolens (Ocular Latina
SLT Gonio Laser Lens, Ocular Instruments, USA) was
placed on the eye and a series of 70-90 non-overlapping shots
was evenly carried out for 360 degrees in mid-trabecular
meshwork. The laser energy was initially selected based on
the intensity of angle pigmentation: 0.4 mJ for eyes with
densely pigmented trabecular meshwork, 0.6 mJ for eyes
with moderate pigmentation, and 0.8 mJ for lower grades of
trabecular meshwork pigmentation, and increased by 0.1-
0.2 mJ until small“champagne bubbles”were observed and
then decreased by 0.1 mJ. All patients were given 0.5%
bethametasone drops 4 times daily for 7d after the procedure,
and instructed to continue routine IOP-lowering medications.
The medications were modified at follow-up visits according
to IOP measurements as needed.
Statistical Analysis The sample size was calculated based
on a difference of at least 1.3 mm Hg in IOP between two
groups, standard deviation of 3 mm Hg and a confidence
interval of 95% . Kolmogorov-Smirnov test and Q-Q plots
were used to evaluate the normality of IOP measurements.
To compare the two study groups, we used -test, Mann-
Whitney test, Chi-square and Fisher exact test, whenever
appropriate. Log-rank test was used to compare survival
curves. Univariate and multivariate Cox's regression analyses
were used to assess factors associated with time to failure.
All statistical analyses were performed with SPSS (version
21.0, Chicago, IL, USA). -values less than 0.05 were
considered statistically significant.
RESULTS
Forty-eight eyes of 46 patients (27 females and 19 males)
who met the eligibility criteria were consecutively enrolled in
the study. There were 27 patients with POAG and 19 patients
with PXFG. In each group, one patient had both eyes
included in the study. The baseline characteristics of the
study subjects are described in Table 1. There were no
significant differences between the two study groups in
baseline characteristics except for gender (with a higher ratio
of female in the POAG group), and IOP, which was higher in
the PXFG group ( =0.025). In the visual fields the average
mean deviation (MD) was -2.88 (依1.67) in the POAG and
-3.1 (依1.69) in the PXFG groups ( =0.3). The number of
patients at each follow-up visit, and changes in IOP and
number of medications from baseline in each study group are
described in Tables 2 and 3.
The mean依SD IOP at baseline and the last visit was 22.9依3.7
and 18.0依3.9 mm Hg in the POAG group ( =0.02), and
25.7依4.4 and 21.0依6.6 mm Hg in the PXFG group( =0.47),
respectively. Mean number of IOP-lowering medications at
baseline was 2.6依0.8 in the POAG group and 2.5依0.8 in
the PXFG group, which decreased to 2.4依1.1 and increased
to 2.7依0.6 at the last follow-up visit, respectively. The differences
were not statistically significant in both groups ( =0.16,
0.57). On Kaplan-Meier survival analysis, the success rate
was 75.0% in the POAG group compared to 94.1% in the
PXFG group ( =0.08; Log-rank test) at 6mo, and 29.1% in
the POAG group and 25.0% in the PXFG group at 12mo ( =
0.9; Log-rank test; Figure 1). The median time to failure was
6mo in both groups. The percentage of IOP reduction was
statistically significantly ( =0.02) in the PXFG group during
the first 6mo of follow-up (Table 2) that might be related to
higher baseline IOP in PXFG group (Figure 2).
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On univariate analyses, there was no statistically significant
association between time to failure and the following factors:
age, gender, glaucoma type, laterality, diabetes, central
corneal thickness, cup to disc ratio, preoperative IOP and
number of medications, and the percentage of IOP reduction
at postoperative week 1. The only observed complication was
redness without intraocular inflammation in one eye in each
group one day after SLT, which resolved spontaneously after
3d.
DISCUSSION
In this prospective comparative study, we investigated
intermediate-term outcomes of 360-degree SLT in patients
with mild to moderate POAG and PXFG with uncontrolled
IOP despite maximally tolerated IOP-lowering medications.
Although the absolute post-laser IOP measurements were
similar in both study groups at all follow-up visits (except
1d), the percent IOP reduction was statistically significantly
more pronounced in the PXFG group during the first 6mo of
follow-up; this might be attributed to higher baseline IOP in
the PXFG group. The mean number of IOP-lowering
medications was statistically similar in both groups at
baseline and SLT did not significantly reduce the number of
medications at any of the follow-up visits in both groups. In a
retrospective study, Kara [10] similarly reported that the
PXFG patients had significantly higher percentage of IOP
reduction compared to POAG patients over one year of
follow-up [10]. They also found that SLT did not reduce the
number of medications at any follow-up visits in both POAG
and PXFG groups[10]. In another prospective study, Ayala and
Chen [11] found that SLT reduced IOP by about 6-7 mm Hg in
both POAG and PXFG patients one month after the
procedure. Although the reduction was slightly better in their
PXFG patients, the difference was not statistically significant[11].
In our study, the efficacy of SLT decreased over time in both
groups, and this was more pronounced in the PXFG group.
Figure 1 Kaplan-Meier survival curve analysis of event -free
rates between the POAG and PXFG groups.
Figure 2 Graph showing the relationship between baseline IOP
and changes of IOP at month 6 from baseline.
Table 1 The baseline characteristics of the study patients                               , n (%) 
Variables  Total POAG PXFG P 
No. of eyes 48 28 20  
No. of patients 46 27 19  
Age (a) 64.0±9.0 62.2±8.9 68.6±7.5 0.2 
Sex     
Male 19 (41.7) 6 13 0.01 
Female 27 (58.3) 21 6 0.01 
Laterality     
Right eye 20 (41.7) 13 (46.4) 7 (35.0)  
Left eye 28 (58.3) 15 (53.6) 13 (65.0)  
Diabetes mellitus     
No 35 (72.9) 20 (71.4) 15 (75)  
Yes 13 (27.1) 8 (28.6) 5 (25)  
Central corneal thickness 537±31 531.6±31.84 537.6 ±29.9 0.5 
Cup to disc ratio 0.6±0.2 0.570±0.14 0.591±0.17 0.78 
Baseline IOP (mm Hg) 24±4.2 22.9±3.7 25.7±4.4 0.025 
Baseline number of medications 3.0±0.8 2.6±0.8 2.5±0.8 0.84 
Baseline MD (dB) -3.0 ±1.67 -2.88±1.67 -3.1±1.69 0.3 
POAG: Primary open angle glaucoma; PXFG: Pseudoexfoliative glaucoma. 
sx ±
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Our results are similar to Gracner findings in PXFG patients[12].
This study showed that SLT is an effective procedure for
lowering IOP in PXFG and POAG eyes, although the effect
seems to last less in PXFG eyes. In another study, Kara [10]
showed that SLT was more effective in reducing IOP in
PXFG compared to POAG, and the effect did not decrease
over one year of follow-up [10]. They found that IOP
significantly decreased by 4.4 依2.1 mm Hg in the POAG
group and by 6.1 依3.6 mm Hg in the PXFG group at the
12-month follow up[10].
A recent Meta-analysis showed that IOP reduction at 12mo
post-SLT in 35 studies ranged from 6.9% to 35.9% [13].
Although few studies have included other types of glaucoma
than POAG, the efficacy of SLT appears to vary according to
type of glaucoma [8,14]. Overall, it seems that the IOP-lowering
effect of SLT is less in patients with normal tension
glaucoma (range: 14% to 16% ), and relatively greater in
PXFG patients (range: 11% to 32%)[13,15-16] . The result of this
Meta-analysis also showed that medications reduced IOP
more than SLT (0.9 mm Hg more with multi therapy and
0.6 mm Hg more with mono-therapy); however, the
difference was not statistically significant [13]. The effect of
SLT on reducing the number of medications varies in
different studies. While some studies have shown that the
number of medications did not change after SLT, others have
reported that SLT reduced the number for medications[13,15,17-18].
In our study, the mean number of IOP-lowering medications
was statistically similar in both groups at baseline and SLT
did not significantly reduce the number of medications at any
of the follow-up visits in both groups. Lee [19] studied
different predictors of success/failure of SLT in 111 eyes (65
patients) with normal tension glaucoma and POAG [19]. They
reported that higher baseline IOP, use of carbonic anhydrase
inhibitors, thinner retinal nerve fiber layer, and lower day 1
IOP were predictors of success[19]. Their definition for success
was IOP reduction 逸20%. Martow [20] also found that
the only predictive factor of SLT success was the
pretreatment IOP and that glaucoma type including PXF was
not a predictor[20].
Tzimis [21] showed that only baseline IOP was the most
powerful variable in predicting outcome of SLT [21]. In
contrast, no baseline factors were found to be a predictor for
failure after SLT in our study. This may be a factor of the
fairly small sample size of our study since the sample size
was determined for a different outcome measure.
The most common side effects of SLT are IOP spike, anterior
chamber inflammation, eye pain or discomfort, photophobia,
and conjunctival hyperemia [13]. These side effects are
generally transient and minor. The reported incidence of IOP
spike varied from 0 to 62% in different studies [13]. In studies
where prophylactic IOP-lowering medications were used, the
reported incidence was lower (between 0 and 29%)[13]. In our
Table 2 IOP measurements in the study groups at different 
follow-up visits 
Time POAG PXFG 1P 
Baseline    
No. of eyes 28 20  
Value 22.9±3.7 25.7±4.4 0.02 
1d    
No. of eyes 28 20  
Value 17.8±5.1 14.7±4.3 0.03 
Change -5.2±5.0 -11±5.3 <0.001 
Change % -22±20 -42±18 <0.001 
1wk    
No. of eyes 23 20  
Value 19.8±3.6 18.7±4.2 0.33 
Change -3.2±3.2 -7.1±6.2 0.01 
Change % -13±13 -26±21 0.02 
1mo    
No. of eyes 27 20  
Value 18.4±4.9 17.7±4.3 0.61 
Change -4.5±4.0 -7.9±5.6 0.02 
Change % -20±18 -30±19 0.04 
3mo    
No. of eyes 28 20  
Value 18.1±2.7 17.0±3.4 0.22 
Change -4.8±3.0 -8.7±5.8 0.005 
Change % -20±11 -32±19 0.009 
6mo    
No. of eyes 28 20  
Value 18.4±3.2 17.9±4.0 0.62 
Change -4.6±3.0 -7.8±5.5 0.01 
Change % -19±11 -29±17 0.02 
9mo    
No. of eyes 23 17  
Value 17.9±3.3 16.3±1.0 0.96 
Change -4.9±3.5 -6.7±2.9 0.30 
Change % -21±13 -28±11 0.22 
12mo    
No. of eyes 18 15  
Value 18.0±3.9 21.0±6.6 0.32 
Change -3.5±4.2 -4.7±9.3 0.75 
Change % -16±17 -16±32 0.9 
POAG: Primary open angle glaucoma; PXFG: Pseudoexfoliative 
glaucoma. 1t-test.  
sx ±
Table 3 Number of IOP-lowering medications in the study groups at 
different follow-up visits 
Time POAG PXFG 1P 
Baseline 2.6±0.8 2.5±0.8 0.84 
1d 2.5±0.8 2.3±0.9 0.49 
1wk 3.0±3.0 2.3±0.7 0.41 
1mo 3.0±2.3 2.3±0.8 0.10 
3mo 2.4±0.8 2.3±0.7 0.72 
6mo 2.4±0.7 2.4±0.8 1.00 
9mo 2.6±0.9 2.5±1.0 0.75 
12mo 2.4±1.1 2.7±0.6 0.74 
POAG: Primary open angle glaucoma; PXFG: Pseudoexfoliative 
glaucoma. 1Mann-Whitney test.  
sx ±
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study, we did not observe any significant complications
during and after the procedure although we did not use any
prophylactic medication.
This study has some shortcomings. The fairly small number
of patients in our study limited the power of our study for
finding predictors of failure after SLT as mentioned above.
Furthermore, the degree of angle pigmentation was not
recorded in our study and therefore, the potential role of this
variable could not be explored.
In conclusion, we found that 360-degree SLT is an effective
and well-tolerated therapeutic modality in patients with
POAG and PXFG. We found that SLT was more effective
early in the postoperative period in patients with PXFG
compared with patients with POAG. However, the efficacy
of SLT decreased over time and this was more pronounced in
PXFG patients.
ACKNOWLEDGEMENTS
Conflicts of Interest: Miraftabi A, None; Nilforushan N,
None; Nassiri N, None; Nouri-Mahdavi K, None.
REFERENCES
1 Park CH, Latina MA, Schuman JS. Developments in laser
trabeculoplasty. 2000;31(4):315-322.
2 Kramer TR, Noecker RJ. Comparison of the morphologic changes after
selective laser trabeculoplasty and argon laser trabeculoplasty in human
eye bank eyes. 2001;108(4):773-779.
3 Cvenkel B, Hvala A, Drnovsek-Olup B, Gale N. Acute ultrastructural
changes of the trabecular meshwork after selective laser trabeculoplasty
and low power argon laser trabeculoplasty. 2003;33 (3):
204-208.
4 Melamed S, Ben Simon GJ, Levkovitch-Verbin H. Selective laser
trabeculoplasty as primary treatment for open-angle glaucoma: a
prospective, nonrandomized pilot study. 2003;121 (7):
957-960.
5 Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith
SD. Laser trabeculoplasty for open-angle glaucoma: a report by the
american academy of ophthalmology. 2011;118 (11):
2296-2302.
6 Stein JD, Challa P. Mechanisms of action and efficacy of argon laser
trabeculoplasty and selective laser trabeculoplasty.
2007;18(2):140-145.
7 Kagan DB, Gorfinkel NS, Hutnik CM. Mechanisms of selective laser
trabeculoplasty: a review. 2014;42(7):675-681.
8 Ayala M. Long-term outcomes of selective laser trabeculoplasty (SLT)
treatment in pigmentary glaucoma patients. 2014;23 (9):
616-619.
9 Shazly TA, Smith J, Latina MA. Long-term safety and efficacy of selective
laser trabeculoplasty as primary therapy for the treatment of
pseudoexfoliation glaucoma compared with primary open-angle glaucoma.
2011;5:5-10.
10 Kara N, Altan C, Yuksel K, Tetikoglu M. Comparison of the efficacy and
safety of selective laser trabeculoplasty in cases with primary open-angle
glaucoma and pseudoexfoliative glaucoma. 2013;29
(9):500-504.
11 Ayala M, Chen E. Comparison of selective laser trabeculoplasty (SLT) in
primary open angle glaucoma and pseudoexfoliation glaucoma.
2011;5:1469-1473.
12 Grancner T. Intraocular pressure response of capsular glaucoma and
primary open-angle glaucoma to selective Nd:YAG laser trabeculoplasty: a
prospective, comparative clinical trial. 2002;12 (4):
287-292.
13 Wong MO, Lee JW, Choy BN, Chan JC, Lai JS. Systematic review and
meta-analysis on the efficacy of selective laser trabeculoplasty in
open-angle glaucoma. 2015;60(1):36-50.
14 Tokuda N, Inoue J, Yamazaki I, Matsuzawa A, Munemasa Y, Kitaoka Y,
Takagi H, Ueno S. Effects of selective laser trabeculoplasty treatment in
steroid-induced glaucoma. 2012;116 (8):
751-757.
15 Lee JW, Ho WL, Chan JC, Lai JS. Efficacy of selective laser
trabeculoplsty for normal tension glaucoma: 1 year results.
2015;15:1
16 Goldenfeld M, Geyer O, Segev E, Kaplan-Messas A, Melamed S.
Selective laser trabeculoplasty in uncontrolled pseudoexfoliation glaucoma.
2011;42(5):390-393.
17 Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G,
SLT/Med Study Group. Selective laser trabeculoplasty versus medical
therapy as initial treatment of glaucoma: a prospective, randomized trial.
2012;21(7):460-468.
18 Abdelrahman AM, Eltanamly RM. Selective laser trabeculoplasty in
egyptian patients with primary open-angle glaucoma.
2012;19(3):299-303.
19 Lee JW, Liu CC, Chan JC, Lai JS. Predictors of success in selective
laser trabeculoplasty for Chinese open-angle glaucoma. 2014;
23(5):321-325.
20 Martow E, Hutnik CM, Mao A. SLT and adjunctive medical therapy: a
prediction rule analysis. 2011;20(4):266-270.
21 Tzimis V, Tze L, Ganesh J, Muhsen S, Kiss A, Kranemann C, Birth CM.
Laser trabeculoplasty: an investigation into factors that might influence
outcomes. 2011;46(4):305-309.
Selective laser trabeculoplasty in pseudoexfoliative glaucoma primary open angle glaucoma
410
